888.3net新浦京游戏(国际)官网-Best Gaming Platform

Company News
Home > Company > News > Company News > Duoning Enters into a Collaboration with Porton to Empower CGT Industry Development

Duoning Enters into a Collaboration with Porton to Empower CGT Industry Development

Dec. 23, 2022

SHANGHAI, Dec. 21, 2022 -- Shanghai Duoning Biotechnology Co., Ltd. ("Duoning") and Porton Biologics Ltd. ("Porton biologics") announced a strategic collaboration. Based on the one-stop solutions of both sides, this partnership will accelerate the development and commercialization of cell and gene therapy (CGT) and facilitate this sector to scale up.

Site of the signing ceremony

Site of the signing ceremony

As an emerging therapeutic method that can replace conventional measures, CGT shows great potential in the treatment of cancer, genetic diseases and infectious diseases. As product approval and commercialization in this area speed up, the domestic CGT industry will further expand and the market size is expected to reach several billion yuan by 2026. However, due to its wide variety and complex manufacturing process, high costs are incurred in all aspects of R&D and production.

Duoning is a leading one-stop bioprocess solutions provider in China. It can provide diversified product portfolios and highly customized services covering the whole biopharmaceutical process from R&D to commercialization. This partnership that sees a combination of Duoning's mature culture medium platform and single use technology and Porton biologics' end-to-end Contract Development Manufacture Organization (CDMO) platform and sound quality system will efficiently facilitate the commercialization of CGT research results.

Mr. Xie Hua, Senior Vice President of Duoning, said: "It is a great pleasure to work with Porton biologics. Porton biologics has been committed to the CGT field for long, and is a highly recognized CDMO in the industry. We believe our cooperation will further reduce costs in all aspects on the premise of quality assurance. We also look forward to pooling the efforts of all parties to promote industrial upgrade and make this therapy most accessible."

Mr. Ding Yulong, Assistant Vice President of Operation Department of Porton biologics, said: "We are very pleased to sign a contract with domestic industry leader Duoning and we are highly anticipated for our cooperation in upstream and downstream bioprocess, key consumables, equipment and other fields. On the premise of controllable quality and stable process, we will broaden the application of domestic equipment in the CGT sector, optimize production costs, and work together to enhance the development of biomedicine and contribute to human health."

About Duoning

Founded in 2005, Shanghai Duoning Biotechnology Co., Ltd. is dedicated to providing one-stop solutions for biopharmaceutical customers, including products and services for biologics products research, development and commercialization. For more information, please visit: www.duoningbio.com.

About Porton Biologics

Founded in 2018, Suzhou Porton Biologics Ltd. (Portonbio) is located in Suzhou Industrial Park. As a subsidiary of the listed company Porton Pharma Solutions Ltd. (Stock Code: 300363), Porton Biologics has built an integrated CDMO platform covering plasmids, viral vectors and cell therapy for early studies, investigator-initiated clinical trial (IIT), investigational new drug (IND) filing, clinical trials  and commercial production, in order to advance clients' product into clinics and beyond. For more information, please visit: www.portonbio.com.


Media: PR@duoningbio.com

Related Products
Contact Us
  • Tel.: +86 021 6434 0155
  • E-Mail: marketing@duoningbio.com
  • Address: Building 30, No. 1525 Minqiang Road, Songjiang District, Shanghai

Copyright © Shanghai Duoning Biotechnology Co., Ltd. All Rights Reserved Sitemap | Technical Support: Reanod



Duoning Biotechnology

+86 021 6434 0155

XML 地图